Cardiovascular risk factors in patients with moderate to severe psoriasis: Integrated prevalence and safety data from 5 randomized controlled trials of adalimumab - 09/05/15
Doi : 10.1016/j.jaad.2015.02.918
Le texte complet de cet article est disponible en PDF.
Craig Leonardi, Central Dermatology, Saint Louis, MO, United States; Yihua Gu, AbbVie Inc, North Chicago, IL, United States; Dilek Arikan, AbbVie Inc, North Chicago, IL, United States; Winnie Lau, AbbVie Inc, North Chicago, IL, United States; Fouad Amer, AbbVie Inc, North Chicago, IL, United States
Le texte complet de cet article est disponible en PDF.| Dr Craig Leonardi has served as a consultant for AbbVie, Amgen, Dermira, Janssen, Boehringer-Ingelheim, Eli Lilly, Leo, Sandoz, UCB, and Pfizer; has served as an investigator for AbbVie, Amgen, Anacor, Celgene, Coherus, Eli Lilly, Galderma, Janssen, Merck, Pfizer, Stiefel, Leo, Novartis, and Tolmar; and is part of the speakers' bureau for AbbVie. Yihua Gu, Dilek Arikan, Winnie Lau, and Fouad Amer are employees of AbbVie and may hold AbbVie stock or stock options. The authors and AbbVie scientists designed the study and analyzed and interpreted the data. All authors contributed to the development of the content; all authors and AbbVie reviewed and approved the presentation; the authors maintained control over the final content. Medical writing support was provided by Jennifer Han, MS, of Complete Publication Solutions, LLC, Horsham, PA. AbbVie funded the research and medical writing support. |
© 2015
Publié par Elsevier Masson SAS.
Vol 72 - N° 5S1
P. AB227 - mai 2015 Retour au numéro
Article précédent
- Association of psoriasis severity with health-related quality of life, depression, and work productivity
- Cardiovascular serum biomarkers in patients with moderate to severe psoriasis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?